FGEN KYNTRA BIO, INC.: institutional ownership and insider trading
Over the last 12 months insiders bought $53.6K and sold $0 on the open market; over its last four quarters it reported revenue of $4.62M and net income of $183M.
FGEN revenue and earnings
- Quarter ended Jun 30, 2026: revenue −$1.47M, net income $12.0M, EPS 2.96
- Quarter ended Mar 31, 2026: revenue $3.74M, net income −$15.2M, EPS -3.76
- Quarter ended Dec 31, 2025: revenue $1.28M, net income −$14.2M, EPS -3.51
- Quarter ended Sep 30, 2025: revenue $1.08M, net income $201M, EPS 49.61
Recent FGEN insider trades
- May 14, 2026: Wettig Thane bought 2,800 shares ($19.9K)
- Nov 17, 2025: Wettig Thane bought 3,700 shares ($33.8K)
- Jun 30, 2025: Schoeneck James A bought 23,567 shares ($119K)
- Mar 24, 2025: Wettig Thane bought 145,000 shares ($50.8K)
5%+ owners
- Armistice Capital, LLC: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
Are insiders buying or selling FGEN?
Over the last 12 months insiders bought $53.6K and sold $0 of KYNTRA BIO, INC. stock on the open market (SEC Form 4).
What was FGEN's revenue last quarter?
KYNTRA BIO, INC. reported revenue of −$1.47M for the quarter ended June 30, 2026, with net income of $12.0M.